Publications by authors named "Christian A Gordillo"
Article Synopsis
- Hematopoietic cell transplant (HCT) patients often have low antibody levels to diseases like tetanus, diphtheria, and pertussis, and there's been no prior research comparing the effectiveness of DTaP and Tdap vaccines in these individuals.
- A study involving 43 HCT recipients found that those who received DTaP had significantly higher antibody levels for all three vaccine components and a greater number of strong responders compared to those who received Tdap.
- The results suggest that DTaP could be a more effective option for vaccinating HCT patients, leading to better immune responses.
Background: Tocilizumab, an interleukin-6 receptor blocker, has been used in the inflammatory phase of COVID-19, but its impact independent of corticosteroids remains unclear in patients with severe disease.
Methods: In this retrospective analysis of patients with COVID-19 admitted between March 2 and April 14, 2020 to a large academic medical center in New York City, we describe outcomes associated with tocilizumab 400 mg (without methylprednisolone) compared to a propensity-matched control. The primary endpoints were change in a 7-point ordinal scale of oxygenation and ventilator free survival, both at days 14 and 28.
Gastrointestinal side effects are the dose-limiting toxicity of high-dose melphalan (HDM) in autologous hematopoietic stem-cell transplantation, but there are limited contemporary data on the incidence and severity of gastrointestinal toxicity associated with this regimen. We retrospectively studied 100 consecutive patients who received HDM alone or in combination with other conditioning agents. Patients had a median age of 56 (range 20-73); underlying diseases were myeloma (42%), lymphoma (42%), or amyloidosis (16%) and melphalan dosages were 200 (40%), 140 (59%), or 100 mg/m (1%).
View Article and Find Full Text PDFArticle Synopsis
- Cytomegalovirus (CMV) reactivation poses serious health risks for patients after allogeneic hematopoietic cell transplantation (AHCT), and the risk increases with graft versus host disease (GVHD).
- A study analyzed 20 patients who received letermovir beyond 100 days post-transplant and found that only one patient (5%) developed significant CMV infection needing treatment, while no patients developed CMV organ disease.
- Results suggest that extended use of letermovir is effective in preventing clinically significant CMV infections in patients suffering from GVHD.